OBIO
Orchestra BioMed Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.65
+3.67%Year over year
Reported trailing growth
- Revenue
- +986.1%
- EBITDA
- +19.4%
- EBIT
- +18.6%
- EPS
- +45.6%
- Free cash flow
- +1.0%
- Operating cash flow
- +1.8%
Forward estimates
Based on analyst estimates
- Revenue
- -98.5%
- EBITDA
- -67.1%
- EPS
- -54.9%
Three-year CAGR
- Revenue
- +111.6%
- EBITDA
- +15.6%
- EBIT
- +19.4%
- Net income
- +13.6%
- EPS
- +33.1%
- Free cash flow
- +2.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026